Drug reference

Upadacitinib

Immunosuppressant

Also known as Rinvoq

Immunosuppressant

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

AbataceptSevereDatabaseDDInter
AbemaciclibSevereDatabaseDDInter
AcalabrutinibSevereDatabaseDDInter
AdalimumabSevereDatabaseDDInter

Mechanism

Upadacitinib is a Janus kinase inhibitor. At concentrations related to its clinical indications, it exhibits specific mechanisms of action that may differ in tissues. Its effects cannot be automatically extrapolated from serum concentration-derived mechanisms.

Indications

rheumatoid arthritispsoriatic arthritisatopic dermatitis

Dosing

Adult: 2 Guidance on prescribing. prescribed in doses other than multiples of 5 mL. The oral. syringe is marked in 0.5 mL divisions from 1 to 5 mL to. measure doses of less than 5 mL (other sizes of oral syringe. instruction leaﬂet. The 5–mL spoon is used for doses of 5 mL

Contraindications

nonuse during breastfeeding
concurrent use of live vaccines

Side effects

Common

infectionsupper respiratory infectionscoughheadachefeverthrombocytopeniaanemianeutropeniaincreased risk of infections (upper respiratory, sinus, common cold, hepatitis c virus)

Serious

Herpes zoster
tuberculous infections
fungal infections
opportunistic infections
venous thromboembolism
increased risk of serious bacterial, fungal, viral, and opportunistic infections leading to hospitalization or death
higher rate of all-cause mortality, including sudden cardiovascular death
higher rate of certain cancers
higher rate of thrombosis, cardiovascular death, myocardial infarction, and stroke
increased risk of venous thromboembolism
deep venous thromboembolism
pulmonary embolism